A carregar...
Targeting DNA methylation for treating triple-negative breast cancer
Triple-negative breast cancer (TNBC) accounts for 15–20% of all invasive breast cancers and tends to have aggressive histological features and poor clinical outcomes. Unlike, estrogen receptor- or HER2-positive diseases, TNBC patients currently lack the US FDA-approved targeted therapies. DNA methyl...
Na minha lista:
| Publicado no: | Pharmacogenomics |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Future Medicine Ltd
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7026764/ https://ncbi.nlm.nih.gov/pubmed/31755366 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/pgs-2019-0078 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|